ProQuest Investments

Agile Therapeutics, Inc. is a women's healthcare company based in Princeton, New Jersey, dedicated to the research, development, and commercialization of prescription contraceptive products. The company's lead product is Twirla, a once-weekly transdermal contraceptive patch that combines levonorgestrel and ethinyl estradiol, designed to provide a non-daily option for contraception. Agile Therapeutics is also advancing a pipeline of additional products and extensions related to Twirla, including regimens aimed at offering women extended cycles, shorter and lighter periods, and a progestin-only patch for those who cannot or prefer not to use estrogen. Utilizing proprietary Skinfusion technology, the company aims to deliver effective contraceptive solutions that address the unmet health needs of women today. Founded in 1997, Agile Therapeutics continues to focus on innovating women's healthcare options.

Agile Therapeutics, Inc. is a women's healthcare company based in Princeton, New Jersey, dedicated to the research, development, and commercialization of prescription contraceptive products. The company's lead product is Twirla, a once-weekly transdermal contraceptive patch that combines levonorgestrel and ethinyl estradiol, designed to provide a non-daily option for contraception. Agile Therapeutics is also advancing a pipeline of additional products and extensions related to Twirla, including regimens aimed at offering women extended cycles, shorter and lighter periods, and a progestin-only patch for those who cannot or prefer not to use estrogen. Utilizing proprietary Skinfusion technology, the company aims to deliver effective contraceptive solutions that address the unmet health needs of women today. Founded in 1997, Agile Therapeutics continues to focus on innovating women's healthcare options.

Agile Therapeutics, Inc. is a women's healthcare company based in Princeton, New Jersey, dedicated to the research, development, and commercialization of prescription contraceptive products. The company's lead product is Twirla, a once-weekly transdermal contraceptive patch that combines levonorgestrel and ethinyl estradiol, designed to provide a non-daily option for contraception. Agile Therapeutics is also advancing a pipeline of additional products and extensions related to Twirla, including regimens aimed at offering women extended cycles, shorter and lighter periods, and a progestin-only patch for those who cannot or prefer not to use estrogen. Utilizing proprietary Skinfusion technology, the company aims to deliver effective contraceptive solutions that address the unmet health needs of women today. Founded in 1997, Agile Therapeutics continues to focus on innovating women's healthcare options.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.